Laboratory of Medical Genetics, Medical School, National and Kapodistrian University of Athens, St. Sophia's Children's Hospital, 11527 Athens, Greece.
Research University Institute for the Study and Prevention of Genetic and Malignant Disease of Childhood, National and Kapodistrian University of Athens, St. Sophia's Children's Hospital, 11527 Athens, Greece.
Int J Mol Sci. 2024 May 22;25(11):5644. doi: 10.3390/ijms25115644.
, the gene encoding for the Nav1.1 channel, exhibits dominant interneuron-specific expression, whereby variants disrupting the channel's function affect the initiation and propagation of action potentials and neuronal excitability causing various types of epilepsy. Dravet syndrome (DS), the first described clinical presentation of SCN1A channelopathy, is characterized by severe myoclonic epilepsy in infancy (SMEI). Variants' characteristics and other genetic or epigenetic factors lead to extreme clinical heterogeneity, ranging from non-epileptic conditions to developmental and epileptic encephalopathy (DEE). This current study reports on findings from 343 patients referred by physicians in hospitals and tertiary care centers in Greece between 2017 and 2023. Positive family history for specific neurologic disorders was disclosed in 89 cases and the one common clinical feature was the onset of seizures, at a mean age of 17 months (range from birth to 15 years old). Most patients were specifically referred for investigation (Sanger Sequencing and MLPA) and only five for next generation sequencing. Twenty-six variants were detected, including nine novel causative variants (c.4567A>Τ, c.5564C>A, c.2176+2T>C, c.3646G>C, c.4331C>A, c.1130_1131delGAinsAC, c.1574_1580delCTGAGGA, c.4620A>G and c.5462A>C), and are herein presented, along with subsequent genotype-phenotype associations. The identification of novel variants complements SCN1A databases extending our expertise on genetic counseling and patient and family management including gene-based personalized interventions.
SCN1A 基因编码 Nav1.1 通道,表现出优势的中间神经元特异性表达,其功能变异会影响动作电位的起始和传播以及神经元兴奋性,导致各种类型的癫痫。Dravet 综合征(DS)是 SCN1A 通道病的第一个临床描述,其特征是婴儿期严重肌阵挛性癫痫(SMEI)。变异的特征和其他遗传或表观遗传因素导致了极端的临床异质性,从非癫痫状态到发育性和癫痫性脑病(DEE)不等。本研究报告了 2017 年至 2023 年间,希腊医院和三级保健中心的医生转诊的 343 名患者的发现。89 例患者有特定神经障碍的阳性家族史,共同的临床特征是癫痫发作,平均发病年龄为 17 个月(从出生到 15 岁)。大多数患者是专门为(Sanger 测序和 MLPA)进行检查而转诊的,只有 5 例是为下一代测序而转诊的。共检测到 26 个变异,包括 9 个新的致病变异(c.4567A>T、c.5564C>A、c.2176+2T>C、c.3646G>C、c.4331C>A、c.1130_1131delGAinsAC、c.1574_1580delCTGAGGA、c.4620A>G 和 c.5462A>C),并在此呈现,以及随后的基因型-表型关联。新变异的鉴定补充了 SCN1A 数据库,扩展了我们在遗传咨询以及患者和家庭管理方面的专业知识,包括基于基因的个体化干预。